Catalent, Inc. (CTLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTLT POWR Grades
- CTLT scores best on the Growth dimension, with a Growth rank ahead of 74.83% of US stocks.
- The strongest trend for CTLT is in Growth, which has been heading up over the past 179 days.
- CTLT's current lowest rank is in the Quality metric (where it is better than 25.25% of US stocks).
CTLT Stock Summary
- CTLT has a market capitalization of $16,005,318,383 -- more than approximately 88.23% of US stocks.
- Price to trailing twelve month operating cash flow for CTLT is currently 36.46, higher than 87.67% of US stocks with positive operating cash flow.
- For CTLT, its debt to operating expenses ratio is greater than that reported by 81.67% of US equities we're observing.
- If you're looking for stocks that are quantitatively similar to CATALENT INC, a group of peers worth examining would be YUMC, MKC, PKG, RE, and DGX.
- CTLT's SEC filings can be seen here. And to visit CATALENT INC's official web site, go to www.catalent.com.
CTLT Valuation Summary
- In comparison to the median Healthcare stock, CTLT's EV/EBIT ratio is 150% higher, now standing at 27.
- CTLT's price/sales ratio has moved up 2 over the prior 98 months.
Below are key valuation metrics over time for CTLT.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CTLT | 2022-09-01 | 3.3 | 3.3 | 31.6 | 27.0 |
CTLT | 2022-08-31 | 3.3 | 3.3 | 31.5 | 26.9 |
CTLT | 2022-08-30 | 3.3 | 3.3 | 31.9 | 27.2 |
CTLT | 2022-08-29 | 3.4 | 3.5 | 33.0 | 28.0 |
CTLT | 2022-08-26 | 3.8 | 3.9 | 36.7 | 28.8 |
CTLT | 2022-08-25 | 4.0 | 4.0 | 38.4 | 29.9 |
CTLT Growth Metrics
- Its 2 year net cashflow from operations growth rate is now at 41.86%.
- Its year over year price growth rate is now at -3.43%.
- Its 3 year revenue growth rate is now at 89.83%.

The table below shows CTLT's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-06-30 | 4,828 | 439 | 503 |
2022-03-31 | 4,703.2 | 504.3 | 486.9 |
2021-12-31 | 4,483.5 | 441.3 | 563 |
2021-09-30 | 4,177.3 | 446.3 | 546.6 |
2021-06-30 | 3,998 | 433 | 529 |
2021-03-31 | 3,757.4 | 471.4 | 496.8 |
CTLT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CTLT has a Quality Grade of C, ranking ahead of 31.5% of graded US stocks.
- CTLT's asset turnover comes in at 0.461 -- ranking 93rd of 682 Pharmaceutical Products stocks.
- INSM, SPPI, and HSKA are the stocks whose asset turnover ratios are most correlated with CTLT.
The table below shows CTLT's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.461 | 0.342 | 0.125 |
2021-06-30 | 0.469 | 0.338 | 0.131 |
2021-03-31 | 0.459 | 0.332 | 0.129 |
2020-12-31 | 0.447 | 0.323 | 0.086 |
2020-09-30 | 0.451 | 0.322 | 0.082 |
2020-06-30 | 0.456 | 0.318 | 0.073 |
CTLT Stock Price Chart Interactive Chart >
CTLT Price/Volume Stats
Current price | $93.09 | 52-week high | $142.64 |
Prev. close | $91.85 | 52-week low | $86.11 |
Day low | $90.35 | Volume | 172,024 |
Day high | $93.09 | Avg. volume | 1,205,467 |
50-day MA | $104.58 | Dividend yield | N/A |
200-day MA | $106.67 | Market Cap | 16.75B |
Catalent, Inc. (CTLT) Company Bio
Catalent provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The company was founded in 2007 and is founded in Somerset, New Jersey.
Latest CTLT News From Around the Web
Below are the latest news stories about CATALENT INC that investors may wish to consider to help them evaluate CTLT as an investment opportunity.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nektar Therapeutics (NKTR), Catalent (CTLT) and Elevation Oncology (ELEV)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nektar Therapeutics (NKTR – Research Report), Catalent (CTLT – Research Report) and Elevation Oncology (ELEV – Research Report). Nektar Therapeutics (NKTR) Nektar Therapeutics received a Sell rating from J.P. Morgan analyst Jessica Fye yesterday. The company's shares closed last Tuesday at $4.03, close to its 52-week low of $3.02. According to TipRanks. |
Despite Price Cut, RBC Capital Is Bullish On Catalent's Long Term TargetsRBC Capital Markets cut the price target on Catalent Inc (NYSE: CTLT) from $155 to $125 with an Outperform rating. The analyst notes that the company reported mixed Q4 FY22 earnings as revenue was 1% below consensus and EBITDA 1.5% above. Related: Catalent Reports Mixed Q4 Earnings; FY23 Sales Expectation Lags Consensus. Adjusting for foreign exchange, EBITDA guidance did come in below consensus due to supply chain and inflationary pressures and lower expected capacity utilization as COVID busin |
Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward. |
Company News for Aug 30, 2022Companies in The News Are: HTHT,CTLT,MRNA,BA,UPS |
Catalent (CTLT) Q4 2022 Earnings Call TranscriptThank you for attending today's Catalent, Inc. fourth quarter fiscal year 2022 earnings call. Good morning, everyone, and thank you for joining us today to review Catalent's fourth quarter and full fiscal year 2022 financial results. Joining me on the call today are Alessandro Maselli, president and chief executive officer; and Tom Castellano, senior VP and chief financial officer. |
CTLT Price Returns
1-mo | -13.91% |
3-mo | -12.73% |
6-mo | -3.15% |
1-year | -34.60% |
3-year | 80.20% |
5-year | 130.71% |
YTD | -27.29% |
2021 | 23.02% |
2020 | 84.85% |
2019 | 80.56% |
2018 | -24.10% |
2017 | 52.37% |
Continue Researching CTLT
Here are a few links from around the web to help you further your research on Catalent Inc's stock as an investment opportunity:Catalent Inc (CTLT) Stock Price | Nasdaq
Catalent Inc (CTLT) Stock Quote, History and News - Yahoo Finance
Catalent Inc (CTLT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...